secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001171843-25-007004
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026
--------------------------------------------------------------------------------

- Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).
- Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.
- Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.
- CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.
- CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/0001171843-25-007004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/f8k_103125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer